Who Owns Jemperli?
Jemperli is owned by GSK plc, a publicly traded British pharmaceutical company listed on the London Stock Exchange and NYSE under ticker GSK and headquartered in London. GSK acquired the drug, an anti-PD-1 antibody known generically as dostarlimab, through its $5.1 billion purchase of Tesaro in January 2019 and first won FDA approval for it in April 2021. Jemperli generated GBP 861 million in FY2025 sales.
Jemperli Timeline
GlobalOfficial Website
Who Owns Jemperli?
- Parent Company: GSK plc
- Ownership Type: Wholly owned
- Acquisition Year: 2019
- Company Type: Publicly Traded
- Stock Ticker: LSE, NYSE: GSK
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Jemperli | GSK plc | Wholly owned |
Where to Buy
Disclosure: We may earn commission from purchases
Jemperli on AmazonAdvertisement
History of Jemperli
- Founded: 2021
- Founders: AnaptysBio (discovery), Tesaro (development), GSK (marketer)
- Acquired by GSK plc: 2019
The molecule that became Jemperli was discovered by AnaptysBio, a California antibody specialist, which out-licensed it to Tesaro in 2014 as the checkpoint inhibitor race accelerated. Tesaro, already commercializing Zejula in ovarian cancer, pushed dostarlimab into trials focused on tumors with mismatch repair deficiency, the same biomarker niche where pembrolizumab had shown striking responses.
Tesaro's independence ended when GSK agreed to acquire the company in December 2018 for $5.1 billion, completing the deal in January 2019. Under GSK, the pivotal GARNET trial supported an accelerated FDA approval in April 2021 for adults with dMMR recurrent or advanced endometrial cancer. A second accelerated approval followed in August 2021 for dMMR recurrent or advanced solid tumors of any type.
The brand's inflection point was the RUBY trial, which showed a survival benefit when Jemperli was added to chemotherapy in first-line endometrial cancer. In August 2024 the FDA approved Jemperli plus chemotherapy for all adults with primary advanced or recurrent endometrial cancer regardless of biomarker status, expanding the addressable population well beyond the dMMR niche. European regulators granted a parallel approval in early 2025.
Sales have scaled with each expansion: roughly GBP 455 million in 2024, then GBP 861 million in 2025 as GSK pushed into more than 35 countries. A closely watched next step is the AZUR-1 trial in dMMR locally advanced rectal cancer, where early single-center data showed complete clinical response rates that could eventually support surgery-sparing treatment. GSK expects pivotal readouts later in 2026.
Advertisement
About GSK plc
What does GSK own?
GSK owns a portfolio of prescription pharmaceuticals and vaccines. Its key products include Shingrix (shingles vaccine, GBP 3.6 billion in FY2025), Trelegy (respiratory, GBP 3.0 billion), the HIV franchise (GBP 7.7 billion including Dovato and Cabenuva), Arexvy (RSV vaccine), Nucala (respiratory), and Bexsero (meningitis vaccine). GSK previously owned consumer healthcare brands including Sensodyne, Advil, and Centrum, but these were spun off as Haleon plc in July 2022.
Is GSK publicly traded?
Yes, GSK plc is publicly traded on the London Stock Exchange and the New York Stock Exchange, both under the ticker symbol GSK. The company has a dispersed shareholder base dominated by institutional investors including BlackRock and Vanguard. GSK has been publicly traded since its formation in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.
Who is the CEO of GSK?
Luke Miels became CEO of GSK on January 1, 2026, succeeding Dame Emma Walmsley. Miels previously served as GSK's Chief Commercial Officer. Walmsley led GSK for nearly nine years, oversaw the Haleon demerger, and steered the company through the Zantac litigation. She remains with the company until September 30, 2026 to support the transition.
Where is GSK headquartered?
GSK is headquartered in London, United Kingdom. The company's corporate offices are in Brentford, West London. GSK has major operations in the United States (approximately 15,000 employees), Europe, and emerging markets, with manufacturing facilities in the UK, U.S., Singapore, and India.
Advertisement
How many brands does GSK own?
GSK owns a portfolio of approximately 20 key prescription medicines and vaccines. The most significant by revenue are Shingrix, the HIV franchise (Dovato, Cabenuva, Juluca), Trelegy, Nucala, Arexvy, Bexsero, and oncology drugs Ojemda and Blenrep. The company does not own consumer healthcare brands, as these were spun off as Haleon in 2022.
Who owns GSK?
GSK is a publicly traded company with a dispersed shareholder base. No single shareholder controls the company. Major institutional investors include BlackRock, Vanguard Group, and other large asset management firms. The company is governed by a board of directors chaired by Sir Jonathan Symonds, with CEO Luke Miels responsible for day-to-day operations.
What was the Zantac litigation?
Zantac (ranitidine) was withdrawn from the U.S. market in 2020 after the FDA found that it contained NDMA, a probable carcinogen. Approximately 80,000 lawsuits were filed alleging Zantac caused cancer. GSK agreed in October 2024 to pay up to $2.3 billion to settle the U.S. claims without admitting liability. By the end of 2025, GSK had paid GBP 1.9 billion, with the remaining GBP 0.6 billion expected in 2026. The company described the settlement process as materially complete.
- Founded: 2000
- Headquarters: London, United Kingdom
- Company Type: Publicly Traded
- Stock: LSE, NYSE: GSK
- Revenue: GBP 32.7B (FY2025)
- Employees: ~70,000
Where Is Jemperli Made / Based?
- Headquarters: London, United Kingdom
- Manufacturing / Operations: United States, Europe
Jemperli Categories & Tags
Jemperli Sustainability & Ethics
Access and affordability are the principal ethical issues around Jemperli, as with most premium-priced immunotherapies. GSK operates patient assistance programs in the US and tiered access arrangements internationally, though PD-1 inhibitors remain out of reach for many health systems.
Advertisement
GSK itself reports progress toward net zero operations and supply chain emissions targets across its portfolio, which includes Jemperli's manufacture. There is no brand-specific certification to report; the drug is a sterile biologic given by infusion in clinical settings.
Jemperli Recalls & Controversies
Jemperli has not faced a safety recall or major scandal. Its label carries the standard immune-mediated adverse reaction warnings common to all checkpoint inhibitors, covering colitis, pneumonitis, hepatitis, endocrinopathies, and infusion reactions.
The honest caveat around the brand is clinical rather than scandalous: its earliest approvals were accelerated approvals based on response rates in the GARNET single-arm study, a pathway that drew general industry scrutiny during the FDA's 2021 review of accelerated oncology indications. Subsequent randomized RUBY data converted the endometrial cancer indication into a confirmatory-trial-backed approval, substantially de-risking the brand's regulatory position.
Advertisement
Brands Owned by GSK plc
Jemperli Ownership: Pros & Cons
Advantages
- +Owned by a top-tier pharma company with global oncology sales infrastructure
- +First immunotherapy with survival data across all endometrial cancer patients
- +89 percent FY2025 sales growth gives it real scale within GSK
- +Pipeline optionality in rectal and other dMMR cancers
- +Integrated development under one owner since 2019
Considerations
- -Competes against Keytruda, the industry's largest product
- -Indications concentrated in a small number of tumor types
- -Accelerated-approval history required confirmatory trials
- -Biomarker-defined markets limit the addressable population
Advertisement
Frequently Asked Questions About Jemperli
Sources & Further Reading
- GSK FY2025 Results Announcement
- Jemperli Prescribing Information
- FDA Approval Records for Dostarlimab
- GSK Company Profile - /companies/glaxosmithkline
Advertisement
Competitors to Jemperli
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Bristol Myers Squibb | USA | 1989 | Mass market | Global | All Genders | |
| Merck | USA | 2014 | Mass market | Global | All Genders | |
| Bristol Myers Squibb | USA | 2014 | Mass market | Global | All Genders |
Learn More About Competitors
Healthcare PharmaceuticalsCarboplatin
Owned by Bristol Myers Squibb Company
Generic platinum-based chemotherapy drug originally marketed as Paraplatin by Bristol-Myers Squibb and now produced by dozens of manufacturers worldwide.
chemotherapyoncologyplatinum
Healthcare PharmaceuticalsKeytruda
Owned by Merck & Co.
Prescription PD-1 checkpoint inhibitor immunotherapy for multiple cancers, owned by Merck and Co. (NYSE: MRK).
oncologycancer-treatmentimmunotherapy
Healthcare PharmaceuticalsOpdivo
Owned by Bristol Myers Squibb Company
Opdivo (nivolumab) is Bristol Myers Squibb's flagship cancer immunotherapy, an anti-PD-1 antibody approved across more than a dozen tumor types.
prescription-drugoncologyimmunotherapy
Competitive Analysis
Market Positioning: Jemperli competes with 3 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Advertisement
Independent Alternatives to Jemperli
Looking for brands with different ownership structures? These similar brands are not owned by GSK plc, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsTradjenta
Owned by Boehringer Ingelheim
Linagliptin DPP-4 inhibitor for type 2 diabetes, developed by Boehringer Ingelheim and co-marketed with Eli Lilly since its 2011 FDA approval.
diabetestype-2-diabetesdpp-4-inhibitor
Privately Owned
Tradjenta is privately owned, unlike Jemperli which is under a publicly traded parent company.
Healthcare PharmaceuticalsVoraxaze
Owned by SERB Pharmaceuticals
Glucarpidase rescue therapy for toxic methotrexate levels, owned by SERB Pharmaceuticals since its 2021 acquisition of BTG.
oncologyglucarpidasemethotrexate-rescue
Privately Owned
Voraxaze is privately owned, unlike Jemperli which is under a publicly traded parent company.
Healthcare Pharmaceuticals23andMe
Owned by TTAM Research Institute
Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.
genetic-testingdna-kitsconsumer-genomics
Privately Owned
23andMe is privately owned, unlike Jemperli which is under a publicly traded parent company.
Healthcare PharmaceuticalsAdcock Ingram
Owned by Adcock Ingram Holdings Limited
South African pharmaceutical brand behind Panado and Myprodol, now privately held by Bidvest and NATCO Pharma.
pharmaceuticalsotchealthcare
Privately Owned
Adcock Ingram is privately owned, unlike Jemperli which is under a publicly traded parent company.
Healthcare PharmaceuticalsArthrex
Owned by Arthrex Inc.
Orthopedic device brand of privately held Arthrex Inc., specializing in arthroscopic surgery products sold in more than 100 countries.
orthopedic-devicesarthroscopysports-medicine
Privately Owned
Arthrex is privately owned, unlike Jemperli which is under a publicly traded parent company.
Healthcare PharmaceuticalsAvaility
Owned by Availity
The largest real-time health information network in the US, owned by a consortium of major health insurers and Novo Holdings.
healthcare-technologyclearinghouseclaims-processing
Privately Owned
Availity is privately owned, unlike Jemperli which is under a publicly traded parent company.
GSK plc Stock Information
Advertisement
Jobs at GSK plc
Latest News About Jemperli
Advertisement
Related Articles About Jemperli
View more articles
Health
Hospital and Clinic Brand Ownership
HCA Healthcare is the largest for-profit hospital system (190 hospitals, $75.6B revenue). Tenet has 50 hospitals ($21.3B). UHS has 346 behavioral facilities. Fresenius leads dialysis. Explore our database.
Who Brands StaffNov 14, 2026
Hca HealthcareTenet HealthUhs
Health
Eye Care Brand Ownership: Bausch & Lomb to Alcon
J&J Vision (Acuvue) leads contact lenses at 27-30%. Alcon (Novartis spin-off) holds 25-27%. CooperVision has 22-24%. Bausch + Lomb has 12-15%. EssilorLuxottica dominates lenses at 30.7%. Explore our database.
Who Brands StaffNov 13, 2026
Bausch LombAlconCoopervision
Health
Dental Brand Ownership Beyond Colgate and Crest
Colgate holds 41.3% global toothpaste share. P&G (Crest, Oral-B) has 14.1%. Haleon (Sensodyne) has 4.4%. Church & Dwight is the only independent at scale. The oral care market is $47.2B. Explore our database.
Who Brands StaffNov 12, 2026
ColgateCrestOral B
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandgenetic-testing
23andMe
Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.
Brand in Healthcare & Pharmaceuticals
dna-kitsconsumer-genomics
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandmedical-devices
Abbott Medical Devices
Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.
Brand in Healthcare & Pharmaceuticals
cardiovasculardiabetes-care